Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 35
Filter
Add more filters










Publication year range
1.
Neoplasma ; 59(4): 398-408, 2012.
Article in English | MEDLINE | ID: mdl-22489695

ABSTRACT

The aim of this study is to evaluate the biologic importance and prognostic significance of selected clinicopathological parameters in patients with oral (OSCC) and oropharyngeal (OPSCC) squamous cell carcinoma, with emphasis on smoking, protein p16(INK4a) (p16) expression, and human papillomavirus (HPV) status.The study sample consisted of 48 patients with OSCC and 44 patients with OPSCC. Half of the patients were nonsmokers and the other half were gender-, age- and tumor localization-matched smokers. p16 expression was detected in 17/48 (35 %) OSCCs and in 36/44 (82 %) OPSCCs and HPV DNA was present in 7/48 (15 %) OSCCs and in 35/44 (80 %) OPSCCs. The sensitivity and specificity of p16 expression for HPV DNA presence were 0.74 and 0.88, respectively. The OPSCCs were more frequently basaloid (p < 0.001) while the OSCCs were more frequently conventional (p < 0.000001). The OSCCs were more likely to recur locally and to be the cause of death (p = 0.009 in both parameters).The HPV-positive tumors were more frequently localized in oropharynx, were basaloid SCCs and were p16- and HPV-positive (p < 0.000001 in all 4 parameters). The HPV-negative tumors were more frequently localized in oral cavity (p < 0.000001), more frequently asociated with local, regional and locoregional recurence (p = 0.011, p = 0.019 and p = 0.030, respectively) and with tumor-related death (p = 0.003). There was no significant difference with regard to smoking history (p > 0.05). The survival of patients with HPV-positive tumors was significantly longer (median 112 months; 95% CI 54 - 112 months) than that of patients with HPV-negative tumors (median 17 months; 95% CI 12 - 39 months) (p < 0.001). The HPV status of OSCC/OPSCC is an important biological and prognostic parameter and should be examined in all cases, using PCR or immunohistochemical detection of surrogate marker p16. Smoking itself does not seem to be an important prognostic factor.


Subject(s)
Carcinoma, Squamous Cell/mortality , Cyclin-Dependent Kinase Inhibitor p16/metabolism , Mouth Neoplasms/mortality , Neoplasm Recurrence, Local/mortality , Oropharyngeal Neoplasms/mortality , Papillomavirus Infections/mortality , Smoking/adverse effects , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/virology , Case-Control Studies , DNA, Viral , Female , Humans , Immunoenzyme Techniques , Male , Middle Aged , Mouth Neoplasms/metabolism , Mouth Neoplasms/virology , Neoplasm Recurrence, Local/metabolism , Neoplasm Recurrence, Local/virology , Neoplasm Staging , Oropharyngeal Neoplasms/metabolism , Oropharyngeal Neoplasms/virology , Papillomaviridae/genetics , Papillomaviridae/isolation & purification , Papillomavirus Infections/metabolism , Papillomavirus Infections/virology , Polymerase Chain Reaction , Prognosis , Risk Factors , Survival Rate
2.
Vnitr Lek ; 56(8): 810-23, 2010 Aug.
Article in Czech | MEDLINE | ID: mdl-20845613

ABSTRACT

Our paper describes 5 patients with a vascular malformation - angiomatosis. In the first patient, a young man, angiomatosis affected the stomach, intestine, the area of mesenterium and retroperitoneum as well as mediastinum. Angiomatous mass had invaded pelvic bones and vertebrae. Treatment was initiated with interferon alpha in a maximum tolerated dose of 3 million units 3 times a week. Because of low efficacy of interferon alpha, thalidomide was added at a dose of 100 mg per day. Bone pain disappeared following a few applications of zoledronate administered in regular monthly intervals. After 3 years of concomitant administration of interferon alpha and thalidomide, we changed the regimen due to adverse effects and are administering thalidomide and interferon alternatively in 4-monthly intervals. Treatment has resulted in 50% reduction, according to imaging, of angiomatous mass, reduced intensity of disseminated intravascular coagulation and disappearance of clinical signs. The second was a case of multiple angiomatosis affecting the intestine only (multiple intestinal angiodysplasias) where we used thalidomide monotherapy. This treatment reduced blood losses and haemoglobin concentrations rose to normal levels. This male patient had consumed 120 transfusion units per year before the initiation of thalidomide. The third case was a slowly progressing vascular malformation of the face. This vascular malformation troubled its sufferer by spontaneous shortening that could not be resolved surgically because of its fragility. Two years of combined treatment with interferon a 6 million unites 3 times a week and thalidomide 100 mg daily led to a reduction and flattening of the malformation, paling of its colour and ceasing of spontaneous bleeding. This development enabled minor surgery--partial excision of this large vascular malformation. Histology examination confirmed that there was no evidence of new capillary formation. Histological examination thus confirmed efficacy of the treatment. The fourth case involved a patient with large vascular malformations affecting supraclavicular region of the neck and nape in whom radiotherapy was applied (54 Gy) leading to a reduction of the malformation mass by a at least 50%. The fifth is a case of an extensive periorbital lymphangioma that diminished following treatment with interferon alpha. These cases illustrate the benefits of combined treatment including thalidomide and interferon alpha in patients with multiple angiomatosis or large proliferating hemangioma (vascular malformation). If combined treatment with thalidomide and interferon a is not possible, it is beneficial to use thalidomide monotherapy. Radiotherapy is another alternative, although it is necessary to apply doses exceeding 50 Gy which may not be always possible.


Subject(s)
Angiogenesis Inhibitors/administration & dosage , Angiomatosis/drug therapy , Hemangioma/drug therapy , Interferon-alpha/administration & dosage , Thalidomide/administration & dosage , Adult , Aged , Angiomatosis/pathology , Female , Hemangioma/pathology , Humans , Male , Middle Aged
3.
Neoplasma ; 57(3): 264-9, 2010.
Article in English | MEDLINE | ID: mdl-20353279

ABSTRACT

MicroRNAs are endogenously expressed regulatory noncoding RNAs. Previous studies showed altered expression levels of several microRNAs in glioblastomas. In this study, we examined the expression levels of selected microRNAs in 22 primary glioblastomas and six specimens of adult brain tissue by real-time PCR method. In addition, we examined methylation status of MGMT promoter by methylation-specific real-time PCR, as this has been shown to be a predictive marker in glioblastomas. MGMT methylation status was not correlated with response to concomitant chemoradiotherapy with temozolomide (RT/TMZ). MiR-221 (p=0.016), miR-222 (p=0.038), miR-181b (p=0.036), miR-181c (p=0.043) and miR-128a (p=0.001) were significantly down-regulated in glioblastomas. The most significant change was observed for up-regulation in miR-21 expression in glioblastomas (p<0.001). MiR-181b and miR-181c were significantly down-regulated in patients who responded to RT/TMZ (p=0.016; p=0.047, respectively) in comparison to patients with progredient disease. Our data indicate for the first time that expression levels of miR-181b and miR-181c could serve as a predictive marker of response to RT/TMZ therapy in glioblastoma patients.


Subject(s)
Brain Neoplasms/genetics , Dacarbazine/analogs & derivatives , Glioblastoma/genetics , MicroRNAs/analysis , Adult , Aged , Biomarkers, Tumor , Brain Neoplasms/therapy , Combined Modality Therapy , DNA Methylation , DNA Modification Methylases/genetics , DNA Repair Enzymes/genetics , Dacarbazine/therapeutic use , Female , Glioblastoma/therapy , Humans , Male , Middle Aged , Promoter Regions, Genetic , Temozolomide , Tumor Suppressor Proteins/genetics
4.
Pediatr Med Chir ; 28(4-6): 95-100, 2006.
Article in Italian | MEDLINE | ID: mdl-17533904

ABSTRACT

BACKGROUND: The terms megaureter or hydroureteronephrosis are non-specific because indicate various pathologic entities recognise different causes (obstruction, reflux, obstruction-reflux, primary and secondary). An undeveloped renal function in neonatal period makes more difficult the therapeutic approach. Actually the problem is to find the indicators that consent us the individualization of patients more suitable for nonoperative management. METHODS: From 1996 to 2002, we observed 60 patients with 74 megaureters. In 24 cases the diagnosis was antenatal, 6 cases were diagnosed immediately after birth, 13 in the first year of life and 17 after the first year (2y-10y). Patients were classified in two groups based on age; 43 cases diagnosed in the first year of life and 17 after. Both of them were classified in two further groups based on ureteral size and renal function, scintigraphically evaluated. RESULTS: In the first group (A) ureters with 10 mm of dilatation improved in 38.9% of the cases. Were stationary 50% and impaired 11,1% of them. Ureters with dilatation between 7 and 10 mm improved in 24%, were stationary in 72% and impaired in in 4% of the cases. Ureters with less than 7mm dilatation improved in 35.2% and were stationary in 64.8%. In the group A renal scintigraphy MAG3 demonstrated, in the patients with acceptable renal function and washout, an improvement in 65% of the cases. Was stationary in 30% and impaired in 10%. CONCLUSIONS: The grade of dilatation evaluated with ultrasonographic exam and the study of renal function with diuresis renal scintigraphy using Tc-99m MAG3 and washout grade with diuresis renal scintigraphy are remarkable markers for the treatment choice.


Subject(s)
Ureter/abnormalities , Ureter/surgery , Ureteral Obstruction/diagnosis , Ureteral Obstruction/surgery , Child , Child, Preschool , Female , Humans , Male , Nephrectomy , Radiography , Radionuclide Imaging , Radiopharmaceuticals , Retrospective Studies , Technetium Tc 99m Mertiatide , Treatment Outcome , Ultrasonography , Ureter/diagnostic imaging , Ureteral Obstruction/diagnostic imaging , Urologic Surgical Procedures/methods
5.
J Clin Ultrasound ; 29(6): 326-31, 2001.
Article in English | MEDLINE | ID: mdl-11424097

ABSTRACT

PURPOSE: Because sonography identifies abnormalities of the gastroesophageal junction, it is essential to understand the normal sonographic anatomy. The aim of this study was to determine the normal sonographic appearance of the gastroesophageal junction and its variations and to provide measurements of the abdominal esophagus in asymptomatic, healthy children. METHODS: In this prospective study, 124 healthy children (75 boys and 49 girls), aged 2 days-12 years, underwent abdominal sonography. With the patient in a supine position, the transducer was placed under the xiphoid and the ultrasound beam was directed cephalad through the window of the left lobe of the liver. The length of the abdominal esophagus was measured from the point at which it penetrated the diaphragm to the gastroesophageal junction. The thickness was measured on the anterior wall at the midpoint of the abdominal esophagus. RESULTS: The gastroesophageal junction was identified by sonography in all of the children. The mean length of the abdominal portion of the esophagus ranged from 18 mm in the newborns to 34 mm in children older than 6 years. The wall thickness ranged from 2.4 mm to 5.7 mm. CONCLUSIONS: Our results indicate that visualization of the gastroesophageal junction and measurement of the abdominal esophagus are readily achievable with real-time sonography in healthy children.


Subject(s)
Esophagogastric Junction/diagnostic imaging , Ultrasonography/methods , Abdomen/diagnostic imaging , Child , Child Development , Child, Preschool , Esophagogastric Junction/anatomy & histology , Female , Humans , Infant , Infant, Newborn , Male , Prospective Studies , Reference Values , Sensitivity and Specificity
7.
Ann N Y Acad Sci ; 905: 177-87, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10818453

ABSTRACT

The specificity of cellular effects of lysolipid phosphate (LLP) growth factors is determined by binding to endothelial differentiation gene-encoded G protein-coupled receptors (EDG Rs), which transduce diverse proliferative and effector signals. The primary determinants of cellular responses to LLPs are the generative and biodegradative events, which establish steady-state concentrations of each LLP at cell surfaces, and the relative frequency of expression of each EDG R. There are major differences among types of cells in the net effective generation of the LLPs, lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), and in their profile of expression of EDG Rs. The less well characterized secondary determinants of cellular specificity of LLPs are high-affinity binding proteins with carrier and cell-presentation functions, cell-selective regulators of expression of EDG Rs, and cellular factors that govern coupling of EDG Rs to G protein transductional pathways. The roles of components of the LLP-EDG R system in normal physiology and disease processes will be definitively elucidated only after development of animal models with biologically meaningful alterations in genes encoding EDG Rs and the discovery of potent and selective pharmacological probes.


Subject(s)
Cell Division/physiology , Cell Survival/physiology , Lysophospholipids/physiology , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Female , GTP-Binding Proteins/metabolism , Humans , Lysophospholipids/metabolism , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Receptors, Cell Surface/metabolism , Tumor Cells, Cultured
8.
Radiat Res ; 153(2): 131-43, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10629612

ABSTRACT

Ionizing radiation has been reported to cause an irreversible cell cycle arrest in normal human diploid fibroblasts. However, colony survival assays show that even at high doses of gamma radiation, human diploid fibroblasts do not irreversibly arrest, and that a dose-dependent fraction is capable of continued cycling. In this study, we resolve the apparent discrepancy between colony survival assays and the observed radiation-induced prolonged arrest. Using flow cytometry analysis, we have confirmed that human diploid fibroblasts do exhibit a prolonged cell cycle arrest in both G(1) and G(2)/M phases of the cell cycle. However, a single replacement of fresh growth medium stimulated a fraction of the arrested population of cells to transiently re-enter the cell cycle. Daily medium changes stimulated these irradiated human diploid fibroblasts to continue cycling until they were contact-inhibited. Thus the fraction of human diploid fibroblasts which survive radiation exposure and are capable of cycling appears to permanently arrest as a result of nutrient insufficiency. Western blot analysis demonstrated a radiation-induced elevation in TP53 (formerly known as p53) protein levels within 2 h postirradiation, followed by a decrease to levels comparable to those in unirradiated controls. The TP53 and CDKN1A (formerly known as p21) protein levels were indistinguishable after 24 h and remained elevated for a 6-day period of observation in both control and irradiated cultures. Our studies indicate that human diploid fibroblasts are capable of re-entering the cell cycle after exposure to ionizing radiation and that this re-entry is dependent on a constant supply of nutrients provided by fresh medium changes. The fraction of cells capable of resuming cell cycling is consistent with the surviving fraction of cells in colony assays.


Subject(s)
Cell Cycle Proteins , Cell Cycle/radiation effects , Skin/radiation effects , Tumor Suppressor Proteins , Blotting, Western , Cell Line , Cell Survival/radiation effects , Culture Media , Cyclin-Dependent Kinase Inhibitor p21 , Cyclin-Dependent Kinase Inhibitor p27 , Cyclins/metabolism , Diploidy , Dose-Response Relationship, Radiation , Fibroblasts/metabolism , Fibroblasts/radiation effects , Gamma Rays , Humans , Microtubule-Associated Proteins/metabolism , Skin/cytology , Skin/metabolism , Tumor Suppressor Protein p53/metabolism
10.
Cancer Res ; 59(20): 5370-5, 1999 Oct 15.
Article in English | MEDLINE | ID: mdl-10537322

ABSTRACT

Endothelial differentiation gene (edg)-encoded G protein-coupled receptors (Edg Rs)-1, -3, and -5 bind sphingosine 1-phosphate (S1P), and Edg-2 and -4 bind lysophosphatidic acid (LPA). Edg Rs transduce signals from LPA and S1P that stimulate ras- and rho-dependent cellular proliferation, enhance cellular survival, and suppress apoptosis. That high levels of LPA in plasma and ascitic fluid of patients with ovarian cancer correlate with widespread invasion suggested the importance of investigating expression and functions of Edg Rs in ovarian cancer cells (OCCs) as compared with nonmalignant ovarian surface epithelial cells (OSEs). Analyses of Edg Rs by semiquantitative reverse transcription-PCR, a radioactively quantified variant of PCR, and Western blots developed with monoclonal antibodies showed prominent expression of Edg-4 R in primary cultures and established lines of OCCs but none in OSEs. In contrast, levels of Edg-2, -3, and -5 were higher in OSEs than OCCs. LPA stimulated proliferation and signaled a serum response element-luciferase reporter of immediate-early gene activation in OCCs but not OSEs, whereas S1P evoked similar responses in both OSEs and OCCs. Pharmacological inhibitors of Edg R signaling suppressed OCC responses to LPA. A combination of monoclonal anti-Edg-4 R antibody and phorbol myristate acetate, which were inactive separately, evoked proliferative and serum response element-luciferase responses of OCCs but not OSEs. Thus the Edg-4 R may represent a distinctive marker of OCC that transduces growth-promoting signals from the high local concentrations of LPA characteristic of aggressive ovarian cancer.


Subject(s)
Ovarian Neoplasms/chemistry , Receptors, Cell Surface/analysis , Receptors, G-Protein-Coupled , Female , Humans , Insulin-Like Growth Factor II/biosynthesis , Lysophospholipids/pharmacology , Nuclear Proteins/analysis , Ovarian Neoplasms/pathology , RNA, Messenger/analysis , Receptors, Cell Surface/genetics , Receptors, Cell Surface/physiology , Receptors, Lysophosphatidic Acid , Response Elements , Signal Transduction , Sphingosine/analogs & derivatives , Sphingosine/pharmacology , Tetradecanoylphorbol Acetate/pharmacology , Transcription Factors/analysis
11.
Cancer Res ; 59(18): 4732-7, 1999 Sep 15.
Article in English | MEDLINE | ID: mdl-10493533

ABSTRACT

Endothelial differentiation gene-encoded G protein-coupled receptors (Edg Rs) Edg-1, Edg-3, and Edg-5 bind sphingosine 1-phosphate (S1P), and Edg-2 and Edg-4 Rs bind lysophosphatidic acid (LPA). LPA and S1P initiate ras- and rho-dependent signaling of cellular growth. Cultured lines of human breast cancer cells (BCCs) express Edg-3 > Edg-4 > Edg-5 > or = Edg-2, without detectable Edg-1, by both assessment of mRNA and Western blots with rabbit and monoclonal mouse anti-Edg R antibodies. BCC proliferation was stimulated significantly by 10(-9) M to 10(-6) M LPA and S1P. Luciferase constructs containing the serum response element (SRE) of growth-related gene promoters reported mean activation of BCCs by LPA and S1P of up to 85-fold. LPA and S1P stimulated BCC secretion of type II insulin-like growth factor (IGF-II) by 2-7-fold, to levels at which exogenous IGF-II stimulated increased proliferation and SRE activation of BCCs. All BCC responses to LPA and S1P were suppressed similarly by pertussis toxin, mitogen-activated protein kinase kinase inhibitors, and C3 exoenzyme inactivation of rho, suggesting mediation by Edg Rs. Monoclonal anti-IGF-II and anti-IGFR1 antibodies suppressed proliferation and SRE reports of BCCs to LPA and S1P by means of up to 65%. Edg Rs thus transduce LPA and S1P enhancement of BCC growth, both directly through SRE and indirectly by enhancing the contribution of IGF-II.


Subject(s)
Cell Division/drug effects , DNA-Binding Proteins/genetics , I-kappa B Proteins , Immediate-Early Proteins/genetics , Lysophospholipids/pharmacology , Nuclear Proteins/genetics , Receptors, Cell Surface/genetics , Receptors, G-Protein-Coupled , Transcription Factors/genetics , Animals , Antibodies/pharmacology , Antibodies, Monoclonal/pharmacology , Breast Neoplasms , DNA-Binding Proteins/analysis , Female , Gene Expression Regulation, Neoplastic/drug effects , Humans , Immediate-Early Proteins/analysis , Mice , NF-KappaB Inhibitor alpha , Nuclear Proteins/analysis , RNA, Messenger/genetics , Rabbits , Receptors, Cell Surface/analysis , Receptors, Lysophosphatidic Acid , Receptors, Lysophospholipid , Reverse Transcriptase Polymerase Chain Reaction , Sphingosine/analogs & derivatives , Sphingosine/pharmacokinetics , Sphingosine/pharmacology , Transcription Factors/analysis , Transcription, Genetic/drug effects , Tumor Cells, Cultured
12.
Pediatr Surg Int ; 13(8): 607-9, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9799389

ABSTRACT

A newborn with a prenatal diagnosis of right hydroureteronephrosis and enlarged penis is presented. At birth, the baby had an imperforate anus (IA) with a megalourethra; radiologic and ultrasonographic studies showed a left polycystic kidney and right hydroureteronephrosis, right vesicoureteral reflux, and an incomplete urethral duplication with dilatation of the posterior urethra. The IA was corrected on the 1st day of life and a vesicostomy was performed at 1 month. At 1 year of age the valve obstructing the ventral posterior urethra was resected and the vesicostomy was closed. At 14 months the baby underwent a urethroplasty with a vertical preputial tubularized island flap and excision of the penile urethral duplication. Exact knowledge of the malformation was essential in planning the appropriate surgical treatment.


Subject(s)
Anus, Imperforate/surgery , Penis/abnormalities , Penis/surgery , Urethra/abnormalities , Urethra/surgery , Dilatation, Pathologic , Humans , Infant, Newborn , Male , Polycystic Kidney Diseases/diagnostic imaging , Ultrasonography , Vesico-Ureteral Reflux/surgery
13.
Folia Biol (Praha) ; 43(1): 49-51, 1997.
Article in English | MEDLINE | ID: mdl-9158951

ABSTRACT

Using a set of overlapping peptides of the human p53 protein, we have performed an accurate mapping of the p53 antigenic sites, recognized by a panel of 19 monoclonal antibodies from the Bp53 series. The results show that most of the antibodies recognize determinants localized in the amino-terminal domain of the protein. Several antibodies reacted with peptides which correspond to the antigenic determinants localized in the carboxy terminus of p53. None of these antibodies reacted with peptides in the central DNA-binding domain of p53 protein.


Subject(s)
Epitopes/analysis , Tumor Suppressor Protein p53/chemistry , Tumor Suppressor Protein p53/immunology , Amino Acid Sequence , Antibodies, Monoclonal , Antibody Specificity , Humans , Molecular Sequence Data , Peptide Mapping
14.
Br J Cancer ; 71(6): 1253-6, 1995 Jun.
Article in English | MEDLINE | ID: mdl-7779720

ABSTRACT

We analysed antibodies specific for human p53 in sera from primary breast cancer patients using three different immunoassays and we related these results to the p53 level in tumour tissue detected by immunohistochemistry. Only 44% (11/25) of apparently enzyme-linked immunosorbent assay (ELISA)-positive sera were from patients with a high level of p53 protein in more than 50% of their tumour cells. Surprisingly, 36% (9/25) of the sera originated from patients with no detectable p53 protein at all. Immunoprecipitation data suggested that the reason for this discrepancy is that at least some of the antibodies detected as positive in the ELISA in these sera from patients with clinical stage I and stage II breast cancers may be induced by immunogens other than p53 protein. Many of these reactions give apparently positive signals in a variety of p53 assays, and very stringent analysis is required to avoid possible misinterpretation of these responses as a p53-specific B-cell response in human cancer patients.


Subject(s)
Autoantibodies/blood , Breast Neoplasms/immunology , Tumor Suppressor Protein p53/immunology , Blotting, Western/methods , Breast Neoplasms/blood , Breast Neoplasms/pathology , Cell Line , Enzyme-Linked Immunosorbent Assay/methods , Female , Fibrosarcoma , Humans , Immunoassay/methods , Immunohistochemistry , Neoplasm Staging , Osteosarcoma , Recombinant Proteins/immunology , Reference Values , Reproducibility of Results , Tumor Cells, Cultured , Tumor Suppressor Protein p53/analysis , Vulvar Neoplasms
15.
Oncogene ; 10(2): 389-93, 1995 Jan 19.
Article in English | MEDLINE | ID: mdl-7530828

ABSTRACT

The p53 protein contains a protease resistant core section that binds to DNA in a sequence specific manner and whose crystal structure has been determined. This core is flanked at the N-terminus by the transcriptional transactivation domain and at the C-terminus by sequences involved in the oligomerisation of the protein. Extensive immunochemical analysis of p53 has shown that dominant antigenic sites lie within these N- and C-terminal domains while few antibodies to the central core have been identified. One of these, PAb240, has been extensively characterised as its epitope is cryptic in the native DNA binding core structure but is exposed by denaturation. This epitope is also exposed on many p53 proteins that contain point mutations in the core domain suggesting that these mutations may have a common affect on the structure of the core. To investigate this further we have generated several new antibodies to novel sites on p53 and mapped their epitopes using synthetic peptides. We find that antibodies to two other discrete sites in the core can also, like PAb240, recognize cryptic epitopes and distinguish mutant from wild-type conformations implying that the point mutations found in p53 in human tumours have widespread effects on the folding pattern of the DNA binding domain.


Subject(s)
Antibodies, Monoclonal , Protein Conformation , Tumor Suppressor Protein p53/chemistry , Amino Acid Sequence , Binding Sites , Epitopes , Humans , Molecular Sequence Data , Point Mutation , Tumor Cells, Cultured , Tumor Suppressor Protein p53/immunology
16.
Neoplasma ; 42(6): 331-6, 1995.
Article in English | MEDLINE | ID: mdl-8592576

ABSTRACT

We have analyzed p53 protein expression in 121 primary breast cancer biopsies by immunohistochemistry using the monoclonal antibody DO-1 and polyclonal serum CM-1. p53 protein overexpression has correlated in our study with mitotic activity (p=0.001), nuclear atypia (p=0.002), less favorable histological type of tumor and in a lesser extent with tumor size. The inverse, but highly significant, correlation (p=0.007) has been observed with lymph node involvement. There was also a trend for higher p53 positivity among DNA aneuploid tumors as compared with DNA diploid cases, but this was not significant. Our study suggests that p53, at least in some patients, may not be directly involved in the process of metastatic progression in breast cancer. Preliminary data would suggest that the detection of p53 protein overexpression could be a useful additional prognostic parameter in breast cancer.


Subject(s)
Breast Neoplasms/chemistry , Tumor Suppressor Protein p53/analysis , Aged , Aged, 80 and over , Breast Neoplasms/pathology , DNA, Neoplasm/analysis , Humans , Immunohistochemistry , Lymphatic Metastasis , Prognosis
17.
Acta Paediatr ; 83(7): 714-8, 1994 Jul.
Article in English | MEDLINE | ID: mdl-7949800

ABSTRACT

The association between breast feeding and acute lower respiratory infection (ALRI) was studied in a case-control study in southern Italy. Two groups of children were studied: the first group comprised 73 infants, aged 0-6 months, whose diagnosis was pneumonia or bronchiolitis; the second group included 88 infants less than 12 months of age with a diagnosis of pertussis-like illness. Control infants were two groups of infants admitted to the same ward. Compared with controls, infants in the first group were less likely to have been breast fed (odds ratio 0.42, 95% CI 0.19-0.90). The protection conferred by breast feeding was stronger among infants who were receiving human milk at the time of admission (odds ratio 0.22, 95% CI 0.09-0.55) and was absent among those infants who had stopped breast feeding for two or more weeks before admission. Among infants who were severely ill, breast feeding was less likely than among those with milder illnesses. There was evidence in the stratified analysis of effect modification by the presence of other children in the family. Among the infants with pertussis-like illness, the incidence and duration of breast feeding were not different compared with controls. The results suggest that breast feeding has a strong protective effect against ALRI in industrialized countries also. No protection seems to be conferred by human milk against pertussis-like illness.


Subject(s)
Breast Feeding , Bronchiolitis/epidemiology , Pneumonia/epidemiology , Population Surveillance , Whooping Cough/epidemiology , Acute Disease , Bronchiolitis/etiology , Case-Control Studies , Confidence Intervals , Effect Modifier, Epidemiologic , Family Characteristics , Female , Hospitalization , Humans , Infant , Infant, Newborn , Male , Odds Ratio , Pneumonia/etiology , Risk Factors , Severity of Illness Index , Whooping Cough/etiology
18.
Pediatr Med Chir ; 11(3): 333-6, 1989.
Article in Italian | MEDLINE | ID: mdl-2594563

ABSTRACT

The neurologically normal children affected by v.u. reflux frequently have miction disorders. The bladder-sphincter dysfunction can determine high intravesical pressures causing distortion of the vesico-ureteral junction in the same way of anastomotic obstruction. The urodynamic study allows the diagnosis of bladder-sphincter dysfunction and the careful therapeutic management. The medical treatment of the dysfunctional voiding may improve the evaluation of the reflux and reduce postoperatively complications and urinary tract infections. The Authors analyse their experience in the medical treatment of 40 children with vesico-ureteral reflux associated with miction disorders. The reflux resolved after medical treatment in 25% of cases and miction disorders in 50% of cases. The Authors stress the importance of careful diagnosis and treatment to improve results in this group of patients.


Subject(s)
Muscle, Smooth/physiopathology , Urethra/physiopathology , Urinary Bladder/physiopathology , Urination Disorders/complications , Vesico-Ureteral Reflux/etiology , Child , Child, Preschool , Female , Humans , Male , Manometry , Radiography , Vesico-Ureteral Reflux/diagnostic imaging
20.
Radiol Med ; 71(10): 657-64, 1985 Oct.
Article in Italian | MEDLINE | ID: mdl-4089247

ABSTRACT

One hundred thirteen children referred for chronic constipation were examined by means of diagnostic work-up including anal inspection, rectal exploration, weekly bowel frequency evaluation, measurement of total and segmental intestinal transit times (TITT, SITT), contrast enema, anorectal manometry (ARM), suction rectal biopsy for histochemistry. Final diagnosis were: chronic functional "simple" constipation in 53 children; chronic functional constipation and soiling in 32; Hirschsprung's disease in 18. In 10 children, initially referred for constipation, TITT was in the normal range so they underwent no further examination. Conclusions are that bowel frequency identifies a real gastrointestinal problem, but definite diagnosis of constipation is relied on TITT. In the assessment of chronic constipation nature, ARM is more sensitive than radiology. Suction rectal biopsy is reliable in detection of aganglionosis: its accuracy can be improved by histochemical or biochemical determination of Acetylcholinoesterase.


Subject(s)
Constipation/diagnostic imaging , Intestines/diagnostic imaging , Acetylcholinesterase/analysis , Adolescent , Anal Canal/physiology , Barium Sulfate , Biopsy , Child , Child, Preschool , Constipation/diagnosis , Constipation/etiology , Enema , Female , Hirschsprung Disease/diagnosis , Hirschsprung Disease/diagnostic imaging , Humans , Infant , Intestinal Mucosa/enzymology , Male , Manometry , Radiography , Rectum/enzymology , Rectum/pathology , Rectum/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...